Trajectories of mHealth-tracked mental health symptoms and

their predictors in chronic pelvic pain

Emily L. Leventhal, B.A.,[1,2] Nivedita Nukavarapu, Ph.D.,[1,2] Noemie Elhadad, Ph.D.,[3] Suzanne

Bakken, Ph.D., RN, FAAN, FACMI, FIAHSI,[4] Michal Elovitz, M.D.,[6] Robert Hirten, M.D.,[7]

Jovita Rodrigues, M.S.,[1,2] Matteo Danieletto, Ph.D.,[1,2] Kyle Landell, B.A.,[1,2] and Ipek Ensari,

Ph.D.[1,2]

[1]*Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount*

Sinai, New York, NY, USA

[2]*Hasso Plattner Institute for Digital Health Mount Sinai, New York, NY, USA*

[3]*Department of Biomedical Informatics, Columbia University Irving Medical Center, New York,*

NY, USA

[4]*Columbia University School of Nursing, Columbia University Irving Medical Center, New York,*

NY, USA

[6]*Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at*

Mount Sinai, New York, NY, USA

[7]*The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at The*

Mount Sinai Hospital, New York, NY, USA

Abstract

Background. Female chronic pelvic pain disorders (CPPDs) affect 1 in 7 women

worldwide and are characterized by psychosocial comorbidities, including reduced quality of life

and 2-10 fold increased risk of depression and anxiety. Despite its prevalence and morbidity,

CPPDs are often inadequately managed with few patients experiencing relief from any medical

intervention. Characterizing mental health symptom trajectories and lifestyle predictors of

mental health is a starting point to enhancing patient self-efficacy in managing symptoms. Here,

we investigate the association between mental health, pain, and physical activity (PA) in females

with CPPD and demonstrate a method for handling multi-modal mobile health (mHealth) data.

Method. The study sample included 4,270 person-level days and 799 person-level weeks of data

from CPPD participants (N=76). Participants recorded PROMIS global mental health (GMH)

and physical functioning, and pain weekly for 14 weeks using a research mHealth app, and

moderate-to-vigorous PA (MVPA) was passively collected via activity trackers. **Data analysis.**

We used penalized functional regression (PFR) to regress weekly GMH-T (GMH-T) on MVPA

and weekly pain outcomes, while adjusting for baseline measures, time in study, and the random

intercept of the individual. We converted 7-day MVPA data into a single smooth using spline

basis functions to model the potential non-linear relationship. **Results**: MVPA was a significant,

curvilinear predictor of GMH-T ($p<0.001$), independent of pain measures and prior psychiatric

diagnosis. Physical functioning was positively associated with GMH-T, while pain was

negatively associated with GMH-T ($\beta=2.24$, $\beta=-1.16$, respectively; $p<0.05$). **Conclusion**: These

findings suggest that engaging in MVPA is beneficial to the mental health of females with

CPPD. Additionally, this study demonstrates the potential of ambulatory mHealth-based data

combined with functional models for delineating inter-individual and temporal variability.

Keywords

Chronic pelvic pain; digital health; functional data modeling; global mental health.

Corresponding author

Emily Leventhal, B.A., 3 E 101st Street, New York, NY 10029,

emily.leventhal@icahn.mssm.edu

Introduction

Described as a "neglected reproductive health morbidity," chronic pelvic pain (CPP) is a

highly debilitating condition that affects between 5.7% and 26.6% of women worldwide.[1–3] CPP,

which encompasses complex CPP disorders (CPPDs) such as endometriosis, adenomyosis, and

fibroids, is characterized by non-cyclic pain in the pelvis or abdomen that lasts for at least 6

months and leads to functional disability or the necessity for medical intervention.[3–5] Its severity

is underscored by its associated physical, psychological, and emotional, and social

consequences.[4,5]

The strong psychosocial impact of CPPDs contributes to their morbidity. For example,

individuals with CPPDs are more likely to experience reduced quality of life, emotional well-

being, productivity, and sexual function compared to the general population.[4] Additionally,

CPPD patients have a significantly higher risk of comorbid psychiatric disorders.[4,6,7]. For

example, individuals with CPPDs have been reported to experience depressive disorders at a

prevalence of 2 to 10 times that of the general population and anxiety disorders 3 to 6 times that

of the general population.[4] Because chronic pain is tightly linked to mental health problems,

investigation of potentially modifiable predictors of mental well-being in individuals with

CPPDs may be a starting point for comprehensively managing and treating CPPD patients.[8]

66   Despite its prevalence and burden, CPP is often inadequately managed, with less than

half of patients experiencing pain relief from any medical treatment.[6,9] Patient self-management,

which encompasses active efforts to manage pain and its effects on physical and emotional

function, is a common chronic pain care model intervention, and it has been associated with

significant improvement in symptoms.[10,11] Further, Center for Disease Control (CDC) guidelines

state that non-opioid and non-pharmacologic therapies should be prioritized for chronic pain

management.[12,13] Non-pharmacological self-management strategies, especially those that target

mental health outcomes of CPPD patients, are needed for effective personalized treatment of

CPPD.

75   Physical activity (PA), and exercise, defined as planned, structured, and repetitive PA

with the goal of improved health or fitness, have been demonstrated to be effective pain self-

management for both reducing pain severity and improving psychological function in chronic

pain patients.[11,14] Experts recommend that chronic pain patients exercise on a regular schedule on

the premise that avoiding activity during pain and increasing intensity later may lead to pain

flares.[4] Importantly, exercise is a modifiable behavior that can also improve pain self-efficacy,

defined as the confidence in one's ability to function effectively while in pain, which is

associated with improved quality of life.[15,16] Further, for chronic pain patients with comorbid

psychiatric conditions, exercise may improve mood, depression, and anxiety symptoms.[4] A

previous study with individuals with endometriosis estimated a small but statistically significant

favorable effect of exercise on pain severity.[17] However, this study relied on self-reported

exercise, which is limited in its ability to capture more granular PA parameters (eg, step counts,

intensity-level).[17] While most of the evidence connecting PA to psychosocial improvement has

been from other chronic pain conditions, yoga has previously been demonstrated to be

efficacious for improving pain and quality of life for patients with endometriosis.[4] The impact of

broader PA on mental health in patients with CPP specifically remains to be investigated, with a

focus on using longitudinal data to capture potentially meaningful trends over time.

CPPDs and their symptomatic patterns are notably heterogeneous in clinical presentation

both between patients and within-individuals over time.[18] Capturing these fluctuations under

ecologically valid circumstances can help improve our understanding of the dynamic unfolding

of these symptoms and their potential predictors. In the context of health behaviors such as PA,

data from mobile health (mHealth) technologies (eg, smartphone apps, trackers) combined with

longitudinal analytic techniques can help elucidate symptom associations with psychosocial

outcomes in CPP.[7,18] For example, there may be non-linear associations and cumulative effects

in these longitudinal data that are not possible to capture via linear modeling approaches. In sum,

flexible techniques can be particularly useful when considering variables that differ in sampling

frequencies, missingness patterns, modality, and temporal complexity, which is often the case

with mHealth data.

Functional regression models, which are a part of the family of generalized additive

models (GAMs), constitute one such approach.[19] In a functional regression framework, the entire

data curve is considered as the unit of analysis, instead of discrete data points in a set of

longitudinal data. This is particularly useful for handling PA data from wearables, rather than

aggregating multiple data points per individual,[20] as they allow investigating the associations

between scalar and functional variables with different time intervals. One example of a scenario

relevant to this study is consideration of continuous or daily PA data with weekly self-reported

survey data, in a repeated-measures design. This results in a data structure where each weekly

questionnaire corresponds to 7 days of PA data leading up to the survey data. A functional

regression model considers the PA data as a weekly data curve rather than aggregating the entire

week into a summary score and thus preserves the temporal pattern within the data. This can

reveal important information that may be lost otherwise, such as periods of inactivity or bursts of

activity, which could be related to mental health.[4,21]

Accordingly, this study aims to characterize the patterns of association between self-

reported mental health symptoms and their predictors in CPPDs, with a focus on modifiable

lifestyle factors. Specifically, this overall aim includes investigation of 1) between- and within-

individual fluctuations in weekly self-reported mental health, and 2) possible modifiable and trait

predictors of weekly mental health. We hypothesized that there would be significant variability

in the mental health both between and within individuals and that PA would be a positive non-

linear predictor of mental health.

123   **Methods**

Study Design and Procedures

The study design and procedures were approved by the IRB of the Icahn School of

Medicine at Mount Sinai (ISMMS; IRB# STUDY-22-01002). This is a secondary analysis of the

data from an ongoing larger study that aims to design, develop, and evaluate CPPD-specific

mHealth measures from patient generated health data with high complexity and temporality

using non-linear distributed lag and functional data modeling (NIH/NICHD: R01HD108263). It

uses an observational study design to collect 90 days of data on patient self-tracked symptoms

via a research mHealth app (ehive[22]) and passively collected activity data using activity trackers

from participants. All participants used the ehive research study app for providing the baseline

and weekly data on overall health, symptoms, well-being and health behaviors, as well as for

receiving prompts and reminders about the study.[22] Participants were instructed to wear a Fitbit

for the duration of the study.

Study Sample

The study sample included individuals who met the following eligibility criteria for the

parent study: 1) females who menstruate currently, between the ages of 18 and 64, 2) self-

reported CPPD based on clinician diagnosis, 3) experience of CPP for at least 6 months, and 4)

ability to read and write in English. Exclusion criteria include: 1) current pregnancy, a birth in

the past 6 months, or planning pregnancy during the months of the study and 2) major diseases or

comorbidities (eg, active cancer, acute coronary syndrome within the past 3 months) that might

confound the outcomes of the primary pelvic pain-related condition. Participants were recruited

from all campuses of the Mount Sinai Health System (MSHS) and Columbia University Irving

Medical Center (CUIMC) via email advertisements and on the myChart by EPIC mobile app for

MSHS patients.

Enrollment

Interested patients reached out to the study coordinator at Mount Sinai for screening and

enrollment, after which they were onboarded and oriented to the study app and data collection

protocols. All participants were mailed a Fitbit Inspire 2 device and instructed to use for the

duration of the study (90 days). Participants were remunerated $15 for every 2 weeks of data

collection and $20 for the final week (ie, up to $120 in total for completing 90 days of data

collection). All participants provided informed consent prior to enrolling in the study.

Study Measures

Primary Outcomes

Self-reported mental health was assessed every week using the PROMIS Global Mental

Health Questionnaire (GMH; 2a, v1.2).[23] The GMH includes 2 questions: 1) "In general, how

would you rate your mental health, including your mood and your ability to think?" 2) "In

general, how would you rate your satisfaction with your social activities and relationships?" Both

questions have a 5-point multiple choice response scale (1-not at all, 5-very much) and the

responses are added to compute the total score on the GMH (range 2-10). Higher scores

represent better mental health.[23] The two-item GMH survey provides a brief measure of mental

health that has been found to be both reliable and have construct validity.[23] Scores from the

GMH survey have been positively associated with other self-reported outcomes including overall

quality of life and physical functioning, and negatively correlated with fatigue, anxiety, anger,

depressive symptoms, and chronic conditions (e.g,. liver disease, kidney disease, hypertension,

etc.).[23] We converted raw GMH scores to population-standardized GMH scores (T-scores)

according to the PROMIS Global Health scoring manual by standardizing the raw total score to a

mean of 50 and a standard deviation (SD) of 10.[24] GMH T-scores (GMH-T) are further

categorized as excellent (>55), very good (48-55), good (40-47), fair (29-39), and poor (<29).[25]

Predictors

Physical activity. Daily minutes of moderate-to-vigorous intensity PA (MVPA) and step

counts were obtained from the wrist-worn Fitbit devices. Participants were instructed to wear

their devices continuously for the study duration. The study app (ehive) allows the user to link

their account with their Fitbit device,[22] which enables regular daily data synching on the backend

of the app. Fitbit uses its proprietary algorithms for detection of step counts and activity

intensities. We collected 6,341 days of physical activity data for 78 participants. For wear time

validation, we relied on the commonly used standard "10-hour minimum wear" rule, in which a

valid day is defined as at least 10 hours of non-zero activity counts.[26–28] Ten hours of wear has

been shown to be sufficient to estimate total daily physical activity during non-sleep time.[29]

There were 4,301 valid days of Fitbit data for 76 participants. Days with unrealistically low

activity counts (eg, <500 steps in a day; n=14) were removed in accordance with similar cutoffs

that have been used in the past to define a valid day, although we used a more conservative

cutoff.[26,27] This resulted in 4,287 days of physical activity data for 76 participants. If there were

more than 7 days of Fitbit data in between survey responses (ie, if a participant waited more than

7 days before completing the next survey), we only considered the first 7 days of Fitbit activity

data to avoid sparsity in the penalized functional regression (PFR) model (described below). 77

days of activity data measured more than 7 days after a survey response were removed for this

reason. The final dataset had 4,270 days of data for 76 participants.

Physical functioning. Weekly physical functioning scores were measured using the

PROMIS physical function survey (4a, v1.0).[30] Physical functioning is the self-reported

capability of performing everyday physical activities. The score evaluates functioning of upper

extremities, lower extremities, central regions, and activities of daily living. The 4-item PROMIS

survey assesses the extent to which individuals find difficulty with physical tasks (5-without any

difficulty to 1-unable to do). Scores range from 4 to 20, with higher scores indicating better

physical functioning. We used the physical functioning T-scores in the analyses, which are

standardized to a mean of 50 and a SD of 10 based on a representative population distribution.[30]

Pain. We measured weekly pain levels using the VAS pain intensity item from the short-

form McGill Pain Questionnaire (MPQ-VAS).[31] The MPQ-VAS asks participants to rate the

intensity of their present pain intensity on a scale of 0 (no pain) to 100 (worst imaginable pain).[32]

This type of VAS-based pain assessment is commonly used as a standard practice in clinical

settings to evaluate patient pain status and treatment outcomes.[33,34]

Other covariates. Data on personal demographics and general health were collected via

a baseline questionnaire on the ehive app. We collected age, marital status, ethnicity, and

employment status from the demographics survey. In addition, we used prior psychiatric

diagnosis ("Have you ever been diagnosed with a psychiatric diagnosis by a provider?") as a

covariate from the general health survey.

Data analysis

Descriptive and bivariate analyses

208
209
First, we performed descriptive analyses and investigated bivariate associations between

the weekly-measured survey items. Given the repeated-measures design, we use both person-

level means (ie, a participant's mean score across the 14 weeks) and overall sample means (ie,

mean of means) where necessary to report the overall study average scores from the daily (ie,

steps, MVPA) and weekly (ie, pain, physical functioning T-score, GMH-T) measures. To

analyze the GMH-T, we converted the mean GMH-T for each participant to its corresponding

GMH category (eg, fair, good, excellent, etc.), and computed the percent of participants in each

category.[25] To evaluate sample GMH-T and physical functioning T-scores against known

population means, we used a one-sample T-test to compare the sample means to the population

means. We then computed repeated-measures correlations between GMH-T, physical

functioning, MPQ-VAS, and the sum of MVPA over 7 days using the rmcorr R package, which

evaluates the within-individual association of paired measurements taken two or more times

longitudinally.[35]

Multivariable regression analysis of GMH predictors

To investigate the potential predictors of GMH-T scores at the week level, we

implemented PFR modeling using the R refund library.[20] PFR models are flexible in numerous

ways that are particularly useful for the data in this study. First, they allow for entire data curves

to be units of analysis as opposed to individual data points. Next, they accommodate different

sampling intervals in the outcomes vs predictors, ie, week-level outcome (eg, GMH-T) and

week-level (eg, pain, physical functioning) and day-level (eg, MVPA) predictors. Instead of

aggregating multiple day-level MVPA values for each week, this feature of the PFR allows for

the preservation of temporal variability in MVPA over a week. Third, it allows specification of

random intercepts (ie, individual participants), which is useful for both accommodating a

repeated measures design and for investigation of potential between- vs within-individual

variability in the outcome of interest (ie, GMH-T scores).

We regressed GMH-T on MVPA while considering MPQ-VAS, PROMIS physical

functioning, age, marital status, employment status, and prior psychiatric diagnosis. We further

adjusted for time in study using month-level cyclical encoding, in which each date is mapped

into a cyclic coordinate system using sine-cosine waves and allows the models to infer the

distance between dates based on their sine-cosine coordinates. We converted 7-day MVPA data

into smooths with up to 7 knots using the tensor product basis function[36] to model the potential

non-linear relationship between GMH-T and daily PA. We similarly included the time covariate

as a functional smooth with up to 7 knots.[20] We scaled MPQ-VAS, PROMIS physical

functioning, and age by mean-centering each variable and dividing by its standard deviation. We

included participant and week in study as random effects. Finally, other categorical variables (ie,

psychiatric diagnosis, employment status, and marital status) were included as person-level

linear covariates.[20] We used a generalized additive model as the fitter to estimate the model and

restricted maximum likelihood as the smoothing parameter estimation method, which are the

default recommended methods for the function.[20]

249   **Results**

Study sample

Participants (n=76) provided 799 weeks of survey and 4,270 days of activity data in total

for analysis. Participants had a mean age of 35 years and were mostly employed (76%). Most

participants identified as White (42%) or Hispanic or Latino (17%). In our sample, 28% had at

least one prior diagnosis of a psychiatric condition, including anxiety and mood disorders (Table

1). The CPPD diagnoses included endometriosis (N=51), adenomyosis (N=1), uterine fibroids

(N=2), interstitial cystitis (N=1), inflammatory bowel syndrome (3), and inflammatory pelvic

dysfunction (N=1).

Descriptive and bivariate analyses

The overall sample means of the scores from the daily and weekly measures are reported

in Table 2. Thirty-nine percent of the participants, on average, reported scores that corresponded

to "fair" mental health, with another 39% of the participants on average reporting "good" mental

health (Table 2). The mean GMH-T was 42.166 (95% CI: 40.363-43.969), which is 7.83 SDs

below the population mean (ie, M=50, "very good")[23] and significantly different (t=-8.658, $p <$

.001; Figure 1). The mean physical functioning T-score was 45.19 (95% CI: 43.52-46.853),

which is 0.48 SDs below the population mean (ie, M=50; Figure 1; t = -5.758, $p < .001$).

To characterize the PA patterns in the sample, we compared participants' activity levels

to the published recommendations and CDC/HHS PA guidelines for adults with respect to steps

and MVPA.[37,37–39] On average, participants accumulated 8,313 steps and 38 minutes of MVPA

per day (Table 2). Forty-three percent of the sample engaged in fewer than 7,500 daily steps,

which is the lower threshold recommended for being considered "sufficiently active" (Figure

2a). [38,39] Similarly, 40.9% accumulated fewer than 150 minutes of weekly MVPA recommended

by the PA Guidelines (Figure 2b). [40]

To inspect the bivariate associations between weekly measures, we computed repeated

measures correlations between GMH-T and the other variables. GMH-T were positively

correlated with weekly MVPA ($p<.05$), and physical function T-score ($p<.01$), while they were

negatively correlated with MPQ-VAS ($p<.001$; Figure 3). Weekly MVPA was additionally

positively correlated with physical functioning T-score ($p<.05$) but was not significantly

correlated with MPQ-VAS.

PFR model

We fitted a PFR model to the data to investigate cumulative and non-linear effects of

MVPA on the weekly GMH-T. The best fitting final model explained 72.6% of the variance in

GMH-T ($R^2=0.65$). The smooth of MVPA and time on GMH-T indicated a significant non-linear

relationship (Table S1; Table S2; edf=2.23, $F=18.99$, $p<.001$). Predicted GMH-T increased with

increasing daily MVPA minutes (Figure 4a). Over time, the largest positive effect of MVPA on

predicted GMH-T as reported at the end of the week was a few days prior (~day 4). The positive

effect of MVPA on GMH-T reported at the end of the week diminished after day 4, suggesting

the positive effects of MVPA lagged by a couple of days. Weekly MPQ-VAS was a significant

negative predictor of GMH-T ($\beta=-1.16$, SE=0.50, $t=-2.34$, $p<.05$), while physical functioning T-

score was a significant positive predictor of GMH-T (Figure 4b; Table S3; $\beta=2.24$, SE=0.598,

$t=3.75$, $p<.001$). For demographic factors, age was negatively associated with GMH-T ($\beta=-1.20$,

SE=0.46, $t=-2.58$, $p<.05$), while being employed and married were positively associated with

GMH-T (β=4.01, SE=1.09, t=3.67, p<.001; β=3.60, SE=0.86, t=4.20, p<.001). Prior psychiatric

diagnosis was not a significant predictor of weekly GMH. The random effect of participant was

significant (Figure 4c; edf=33.43, F=2.76, p<0.001). The random effect of week and the

cyclically encoded sine and cosine functions of month were not significant.

Discussion

In this study, we leveraged ambulatory mHealth-tracked mental health, pain, and physical

activity data to characterize longitudinal self-reported mental health patterns of individuals with

CPPDs. Our results indicate a positive, non-linear relationship between PA and mental health,

independent of prior psychiatric diagnosis or other pain-related factors, with considerable

variability both between and within participants over time. To our knowledge, this study

provides the first line of evidence on the positive effect of PA on mental health in females with

CPPDs using repeated measures data collected in real time. We further report lower scores of

mental health and physical functioning compared to the general population, as well as lower PA

levels than those recommended by the PA guidelines.

Our cohort had a 28% incidence of prior psychiatric conditions and lower average global

mental health compared to the general population. Chronic pain, and specifically CPPDs, has

been established as a strong predisposing factor for psychiatric conditions, due to both the

psychosocial impact of chronic pain and common neurobiological vulnerabilities and genetic

factors between chronic pain and mood.[4,6,41,42] CPPD patients with comorbid psychiatric

conditions are more likely to incur higher health care costs, experience lower quality of life,

endure increased disability, and are more likely to be prescribed opioids.[4] Additionally, our

findings add to the literature documenting the worsened mental health of CPPD patients as a

whole compared to the general population.[4,23,42] In the 2019 National Health Interview Survey,

those with chronic pain had a 23.9% prevalence of co-occurring anxiety and/or depression

symptoms, whereas the population without chronic pain had a prevalence of 4.9%.[42] Given the

high incidence of psychiatric co-morbidities and the generally low mental health among CPPD

patients, it is important to treat mental health as part of comprehensive chronic pain management

and continue to determine ways to aid patients to manage their symptoms. As such, here, we

investigated how lifestyle factors may modify the association of CPP with poorer mental health

outcomes.

Our findings suggest that many females with CPPDs do not reach nationally

recommended activity levels, and moreover, that engaging in MVPA is beneficial for the mental

health of CPPD patients. The PA levels found in this sample are consistent with previous studies

indicating that individuals with CPPDs have lower PA levels,[43] though data on CPPDs are

scarce. One longitudinal study using accelerometers indicated that MVPA negatively mediated

the relationship between chronic pain and risk of mental disorders, although this study did not

focus on CPP.[44] Increased MVPA in individuals with chronic pain was associated with decreased

anxiety and depression symptoms, whereas light intensity PA did not have this effect.[42] While

previous studies have established the connection between MVPA and mental health in chronic

pain, this is the first study to establish the relationship between PA and mental health in the

context of CPP by using passively-obtained data from activity trackers.[17]

Our findings further indicate that increased pain is associated with worsened GMH, while

increased physical functioning was associated with improved GMH. Though pain and depression

or anxiety have been noted to have a bidirectional relationship, there is more evidence that pain

is a risk factor for mental health problems than the inverse.[4] Additionally, a longitudinal study

focused on musculoskeletal conditions found that improvements in physical functioning were

associated with improved anxiety symptoms, although it was not associated with improved

depression symptoms.[45] The relationship between physical functioning and mental health in CPP

has not been well defined to this point, however, one previous longitudinal study on

endometriosis reported that functional pain disability did not predict later emotional distress.[46]

With respect to demographic factors as potential predictors, increased age was associated

with worsened GMH, while prior psychiatric diagnosis was not a significant predictor. Age may

be a proxy for years of experience with the chronic pain condition or severity of the condition. In

this study, we did not have a survey item assessing time of initial diagnosis, although this may be

possible in the future by linking mobile health studies with electronic health records (EHRs).

Over time, chronic pain may become more difficult to treat due to structural and functional

neuroplastic changes that eventually become irreversible and insensitive to treatment.[41] From a

psychosocial standpoint, the economic consequences of health care costs and loss of productivity

may accumulate over time.[41] It will be important to assess how length of time of living with

chronic pain impacts mental health in the future. Interestingly, diagnosis with a prior psychiatric

condition, including mood and anxiety disorders, was not a significant predictor of GMH. This

may suggest that some individuals with prior psychiatric diagnoses may not be actively

experiencing symptoms, or alternatively, that this sample has a large number of participants with

undiagnosed psychiatric conditions that are actively experiencing symptoms.

We observed substantial between- and within-individual variability in mental health

scores in the sample, underscoring the importance of personalized approaches to care. Predicted

average GMH-T varied greatly between individuals as shown by the random intercepts. CPPDs

are notoriously heterogeneous in pain symptomatology, and it follows that mental health would

exhibit similar variability among and within participants.[7] As such, it is important to use

individualized approaches, such as that which may be achieved with mHealth, to

comprehensively understand the complexity of CPP. Due to their heterogeneous clinical

presentation and differing etiologies, CPPDs are often non-responsive to treatment, and a

personalized approach is necessary for the successful management of CPPD. To better

understand how to manage the mental health of CPPD patients, we should continue to study

modifiable lifestyle factors, as was done here with PA, that may alter the poor mental health

outcomes associated with CPP. This study demonstrates the potential of using ambulatory

mHealth-based data combined with functional data methods to delineate inter-individual and

temporal variability in symptoms of chronic conditions.

There are numerous strengths of this work. First, we focus on a patient population that

has been under-studied (ie, CPPDs) and currently still not well-understood as a cluster of

disorders with overlapping symptomatology. While endometriosis, the most common underlying

primary diagnosis for a CPPD, has been receiving more attention recently, our sample also

included those less-studied CPP conditions (eg, adenomyosis, fibroids, inflammatory pelvic

disease). Next, implementation of functional data methods and generalized additive modeling

using smooths provide robust, flexible approaches for handling the complex patient-generated

health data from mHealth technologies. The PFR models in this context facilitate the evaluation

of complex relationships between outcomes and their predictors in instances where data

sampling frequency differs between the outcomes and predictors, or between different predictors.

As mHealth use is becoming more ubiquitous for conducting research, expanding upon the

available methods will enable fully harnessing the information from these data. Third, our

analyses were based on frequently-sampled prospective data of up to 14 weeks from the study

participants. This is a strength of the data design as most studies to date are limited to

convenience samples of retrospective data with much less frequency of data points.

Nevertheless, we acknowledge the limitations of this study. Although we had 799 person-

level weeks for analysis, 76 participants is a relatively modest sample size in comparison to

large, nationally-representative cohort studies. Similarly, the sample was somewhat

homogeneous with respect to demographic factors including employment status and education

levels. Third, despite our careful inspection of the missing data and implementing cautious

filtering criteria to prevent potentially erroneous inference from the data, Fitbit's proprietary

algorithms do not always enable as informed decisions regarding the missing data as do some

other devices, such as research grade trackers that allow access to the raw acceleration data. To

circumvent these issues, we conducted a series of sensitivity analyses to assess the pattern of

missingness in the data, as well as the possible influence of missingness on the model results.

Results (not reported herein) indicated no significant bias, suggesting a missing-at-random

(MAR) pattern, or change in model point estimates. Finally, most of the participants had

endometriosis as their primary CPPD, therefore we are not able to delineate differences in mental

health trajectories among different disorders within CPPD.

Conclusions

mHealth-enabled direct patient input and passive tracking via wearables enables the

capturing of real-world data to improve our understanding of inter-individual and temporal

variability in mental health symptoms and factors that may improve mental health. By leveraging

patient-tracked mental health and pain outcomes combined with passively-obtained activity data

from CPPD patients, we demonstrate a positive, non-linear relationship between PA and mental

health in CPP.

Ethics approval and informed consent

The study was approved by the Institutional Review Board (IRB) of the Icahn School of

Medicine at Mount Sinai (IRB# STUDY-22-01002) and all participants provided informed

consent.

Data availability

The data collection for the parent grant is currently ongoing. After completion of the

active grant period, the data produced in the present study will be made available upon

reasonable request to the corresponding author.

Funding

This study was supported by a grant award from the Eunice Kennedy Shriver National

Institute Of Child Health & Human Development of the National Institutes of Health (Award

Number: R01HD108263, PI=Ensari). The content does not necessarily represent the official

views of the National Institutes of Health. Additionally, this research was supported by the T32

grant 1T32GM146636.

Authors' contributions

All authors contributed significantly to the work presented in this manuscript, including

the conception, study design, execution, acquisition of data, analysis and interpretation. Each

author reviewed this article and agree to take responsibility for the contents of this article.

References

1. Latthe P, Latthe M, Say L, Gülmezoglu M, Khan KS. WHO systematic review of prevalence

of chronic pelvic pain: a neglected reproductive health morbidity. *BMC Public Health*.

2006;6(1):177. doi:10.1186/1471-2458-6-177

2. Ahangari A. Prevalence of Chronic Pelvic Pain AmongWomen: An Updated Review. *Pain

Physician*. 2014;2;17(2;3):E141-E147. doi:10.36076/ppj.2014/17/E141

3. Hutton D, Mustafa A, Patil S, et al. The burden of Chronic Pelvic Pain (CPP): Costs and

quality of life of women and men with CPP treated in outpatient referral centers. Raimondo

D, ed. *PLOS ONE*. 2023;18(2):e0269828. doi:10.1371/journal.pone.0269828

4. Till SR, As-Sanie S, Schrepf A. Psychology of Chronic Pelvic Pain: Prevalence,

Neurobiological Vulnerabilities, and Treatment. *Clin Obstet Gynecol*. 2019;62(1):22-36.

doi:10.1097/GRF.0000000000000412

5. Ayorinde AA, Macfarlane GJ, Saraswat L, Bhattacharya S. Chronic Pelvic Pain in Women:

An Epidemiological Perspective. *Womens Health*. 2015;11(6):851-864.

doi:10.2217/whe.15.30

6. Meltzer-Brody S, Leserman J. Psychiatric Comorbidity in Women with Chronic Pelvic Pain.

CNS Spectr. 2011;16(2):29-35. doi:10.1017/S1092852912000156

7. Till SR, Nakamura R, Schrepf A, As-Sanie S. Approach to Diagnosis and Management of

Chronic Pelvic Pain in Women. *Obstet Gynecol Clin North Am*. 2022;49(2):219-239.

doi:10.1016/j.ogc.2022.02.006

8. Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain:

Neural Mechanisms in the Brain. *Neural Plast*. 2017;2017:1-10. doi:10.1155/2017/9724371

9. The Initial Management of Chronic Pelvic Pain. Published online 2012.

10. Kerns RD, Burgess DJ, Coleman BC, et al. Self-Management of Chronic Pain:

Psychologically Guided Core Competencies for Providers. *Pain Med*. 2022;23(11):1815-

1819. doi:10.1093/pm/pnac083

11. Leonardi M, Horne AW, Vincent K, et al. Self-management strategies to consider to combat

endometriosis symptoms during the COVID-19 pandemic. *Hum Reprod Open*.

2020;2020(2):hoaa028. doi:10.1093/hropen/hoaa028

12. Nonopioid Therapies for Pain Management | Overdose Prevention | CDC.

13. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 |

MMWR.

14. Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity and

exercise for chronic pain in adults: an overview of Cochrane Reviews. Cochrane Pain,

Palliative and Supportive Care Group, ed. *Cochrane Database Syst Rev*. 2017;2020(2).

doi:10.1002/14651858.CD011279.pub3

15. Gilanyi YL, Wewege MA, Shah B, et al. Exercise Increases Pain Self-efficacy in Adults

With Nonspecific Chronic Low Back Pain: A Systematic Review and Meta-analysis. *J*

Orthop Sports Phys Ther. 2023;53(6):335-342. doi:10.2519/jospt.2023.11622

16. Kalapurakkel S, A. Carpino E, Lebel A, E. Simons L. "Pain Can't Stop Me": Examining

Pain Self-Efficacy and Acceptance as Resilience Processes Among Youth With Chronic

Headache. *J Pediatr Psychol*. 2015;40(9):926-933. doi:10.1093/jpepsy/jsu091

17. Ensari I, Lipsky-Gorman S, Horan EN, Bakken S, Elhadad N. Associations between physical

exercise patterns and pain symptoms in individuals with endometriosis: a cross-sectional

mHealth-based investigation. *BMJ Open*. 2022;12(7):e059280. doi:10.1136/bmjopen-2021-

059280

18. Ensari I, Pichon A, Lipsky-Gorman S, Bakken S, Elhadad N. Augmenting the Clinical Data

Sources for Enigmatic Diseases: A Cross-Sectional Study of Self-Tracking Data and Clinical

Documentation in Endometriosis. *Appl Clin Inform*. 2020;11(05):769-784. doi:10.1055/s-

0040-1718755

19. Muller HG, Wu Y, Yao F. Continuously additive models for nonlinear functional regression.

Biometrika. 2013;100(3):607-622. doi:10.1093/biomet/ast004

20. Goldsmith J, Bobb J, Crainiceanu CM, Caffo B, Reich D. Penalized Functional Regression. *J*

Comput Graph Stat. 2011;20(4):830-851. doi:10.1198/jcgs.2010.10007

21. Manning JR, Notaro GM, Chen E, Fitzpatrick PC. Fitness tracking reveals task-specific

associations between memory, mental health, and physical activity. *Sci Rep*.

2022;12(1):13822. doi:10.1038/s41598-022-17781-0

22. Hirten RP, Danieletto M, Landell K, et al. Development of the ehive Digital Health App:

Protocol for a Centralized Research Platform. *JMIR Res Protoc*. 2023;12:e49204.

doi:10.2196/49204

23. Hays RD, Schalet BD, Spritzer KL, Cella D. Two-item PROMIS® global physical and

mental health scales. *J Patient-Rep Outcomes*. 2017;1(1):2. doi:10.1186/s41687-017-0003-8

24. Global Health Scoring Manual. Published online August 15, 2021.

25. Elsman EBM, Roorda LD, Crins MHP, Boers M, Terwee CB. Dutch reference values for the

Patient-Reported Outcomes Measurement Information System Scale v1.2 - Global Health

(PROMIS-GH). *J Patient-Rep Outcomes*. 2021;5(1):38. doi:10.1186/s41687-021-00314-0

26. Master H, Annis J, Huang S, et al. Association of step counts over time with the risk of

chronic disease in the All of Us Research Program. *Nat Med*. 2022;28(11):2301-2308.

doi:10.1038/s41591-022-02012-w

27. Perry AS, Annis JS, Master H, et al. Association of Longitudinal Activity Measures and

Diabetes Risk: An Analysis From the National Institutes of Health *All of Us* Research

Program. *J Clin Endocrinol Metab*. 2023;108(5):1101-1109. doi:10.1210/clinem/dgac695

28. Beagle AJ, Tison GH, Aschbacher K, Olgin JE, Marcus GM, Pletcher MJ. Comparison of

the Physical Activity Measured by a Consumer Wearable Activity Tracker and That

Measured by Self-Report: Cross-Sectional Analysis of the Health eHeart Study. *JMIR*

MHealth UHealth. 2020;8(12):e22090. doi:10.2196/22090

29. Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, Mcdowell M. Physical Activity in

501 the United States Measured by Accelerometer. *Med Sci Sports Exerc*. 2008;40(1):181-188.

502 doi:10.1249/mss.0b013e31815a51b3

503 30. Rose M, Bjorner JB, Gandek B, Bruce B, Fries JF, Ware JE. The PROMIS Physical

504 Function item bank was calibrated to a standardized metric and shown to improve

505 measurement efficiency. *J Clin Epidemiol*. 2014;67(5):516-526.

506 doi:10.1016/j.jclinepi.2013.10.024

507 31. Melzack R. The short-form McGill pain questionnaire. *Pain*. 1987;30(2):191-197.

508 doi:10.1016/0304-3959(87)91074-8

509 32. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale

510 for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire

511 (MPQ), Short☐Form McGill Pain Questionnaire (SF☐MPQ), Chronic Pain Grade Scale

512 (CPGS), Short Form☐36 Bodily Pain Scale (SF☐36 BPS), and Measure of Intermittent and

513 Constant Osteoarthritis Pain (ICOAP). *Arthritis Care Res*. 2011;63(S11).

514 doi:10.1002/acr.20543

515 33. Lukacz ES, Lawrence JM, Burchette RJ, Luber KM, Nager CW, Galen Buckwalter J. The

516 use of Visual Analog Scale in urogynecologic research: A psychometric evaluation. *Am J*

517 *Obstet Gynecol*. 2004;191(1):165-170. doi:10.1016/j.ajog.2004.04.047

518 34. Creinin MD. Pain Associated With Cervical Priming for First-Trimester Surgical Abortion:

519 A Randomized Controlled Trial. *Obstet Gynecol*. 2021;138(4):680-680.

520 doi:10.1097/AOG.0000000000004552

521 35. Bakdash JZ, Marusich LR. Repeated Measures Correlation. *Front Psychol*. 2017;8:456.

doi:10.3389/fpsyg.2017.00456

36. Simon Wood <simon.wood@r-project.org>. mgcv: Mixed GAM Computation Vehicle with

Automatic Smoothness Estimation. Published online October 4, 2000:1.9-1.

doi:10.32614/CRAN.package.mgcv

37. Leavitt MO. 2008 Physical Activity Guidelines for Americans.

38. Tudor-Locke C, Craig CL, Thyfault JP, Spence JC. A step-defined sedentary lifestyle index:

<5000 steps/day. *Appl Physiol Nutr Metab*. 2013;38(2):100-114. doi:10.1139/apnm-2012-

0235

39. Tudor-Locke C, Hatano Y, Pangrazi RP, Kang M. Revisiting "How Many Steps Are

Enough?" *Med Sci Sports Exerc*. 2008;40(7):S537-S543.

doi:10.1249/MSS.0b013e31817c7133

40. *Physical Activity Guidelines for Americans, 2nd Edition*. US Department of Health and

Human Services; 2018.

41. Fine PG. Long-Term Consequences of Chronic Pain: Mounting Evidence for Pain as a

Neurological Disease and Parallels with Other Chronic Disease States. *Pain Med*.

2011;12(7):996-1004. doi:10.1111/j.1526-4637.2011.01187.x

42. De La Rosa JS, Brady BR, Ibrahim MM, et al. Co-occurrence of chronic pain and

anxiety/depression symptoms in U.S. adults: prevalence, functional impacts, and

opportunities. *Pain*. 2024;165(3):666-673. doi:10.1097/j.pain.0000000000003056

43. Sachs MK, Dedes I, El-Hadad S, et al. Physical Activity in Women with Endometriosis: Less

or More Compared with a Healthy Control? *Int J Environ Res Public Health*.

2023;20(17):6659. doi:10.3390/ijerph20176659

44. Chen J. The associations of chronic pain and 24-h movement behaviors with incident mental

disorders: evidence from a large-scale cohort study. Published online 2024.

45. Zhang W, Singh SP, Clement A, Calfee RP, Bijsterbosch JD, Cheng AL. Improvements in

Physical Function and Pain Interference and Changes in Mental Health Among Patients

Seeking Musculoskeletal Care. *JAMA Netw Open*. 2023;6(6):e2320520.

doi:10.1001/jamanetworkopen.2023.20520

46. Dowding C, Mikocka☐Walus A, Skvarc D, et al. The temporal effect of emotional distress

on psychological and physical functioning in endometriosis: A 12☐month prospective study.

Appl Psychol Health Well-Being. 2023;15(3):901-918. doi:10.1111/aphw.12415

Table 1. Study sample demographics.
555

Variable	N	Mean or %
Age (years)	72	35
Sex	76	
… female	76	100%
… male	0	0%
Employment status	75	
... employed	57	76%
... other	7	9%
... unemployed	11	15%
Marital status	76	
... divorce	6	8%
... married	35	46%
... single	35	46%
Psychiatric diagnosis	76	
... None	55	72%
... At least 1	21	28%
Race/Ethnicity	76	
... asian	8	11%
... black	11	14%
... hispanic or latino	13	17%
... mixed	7	9%
... unknown	5	7%
... white	32	42%

556
557

558 Table 2. Average weekly and daily measures across the study. The average was taken of the

559 participant means for each repeated measure.

Variable	N	Mean or %
Mean MVPA	76	38
Mean steps	76	8313
Mean MPQ-VAS	75	34
Mean phys. func. T-score	73	45
Mean GMH T-score	75	42
Mean GMH T Category	75	
... Poor	3	4%
... Fair	29	39%
... Good	29	39%
... Very Good	8	11%
... Excellent	6	8%

561
562 **Figure 1**   -   -

563   -   -

564   -   =42.166, 95% CI: 40.363-43.969, M=50, t=-8.658, $p < .001$) and physical

565   -   =45.19, 95% CI: 43.52-46.853, M=50, $t = $ -5.758, $p < .001$) means were

566 significantly different than the general population.

567
568
569

570   A.

571
572   B.

573
574   **Figure 2.** Mean participant **A)** daily step count and **B)** mean weekly MVPA minutes compared

575   to nationally recommended activity levels. The y-axis represents the number of participants.

576   Dashed lines represent the recommended levels (7500 steps, 150 MVPA minutes). The values

577   represent the number of individuals who fell above and below these nationally recommended

578 values.

579
580 **Figure 3.** Repeated measures correlations for weekly measures. MVPA=moderate-to-vigorous

581 physical activity; Phys. Func. T = physical functioning T-score; MPQ-VAS=McGill Pain

582 Questionnaire-VAS; Global Mental Health T=GMH-T

584 A.

585 $\hat{F}(MVPA,t)$

601 B.

Scalar predictors

622 **Figure 4.** Results from the PFR model. **A)** The smooth effect of MVPA on GMH-T over time.

623 The MVPA axis is scaled. The y-axis represents predicted GMH-T and is scaled according to

624   predicted sample GMH-T mean. **B)** Coefficients and confidence intervals for scalar predictors of

625   the model. **C)** Random effect of participant, with each dot representing predicted mean GMH-T

626   for that participant.

                              Supplemental Tables

630   **Table S1.** Smooth predictors of the PFR model.

Predictor	edf	Ref.df	F	p-value
t2(MVPA.tmat,MVPA.omat):L.MVPA	2.23222202	2.40665028	18.9885386	4.0841E-06
s(month_cos.tmat):L.month_cos	2.00001858	2.00003559	0.48641865	0.61566209
s(month_sin.tmat):L.month_sin	2.5591852	2.8159533	0.63612865	0.59048914
s(Participant)	33.4252443	57	2.75714802	1.5399E-06
s(Week)	5.2859E-05	1	5.0264E-06	0.96005532

632
633   **Table S2.** Point estimates for smooth terms.

Predictor	Estimate	SE
scale(pfr_age)	-1.1946	0.4629
t2(MVPA.tmat,MVPA.omat):L.MVPA.1	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.2	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.3	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.4	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.5	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.6	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.7	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.8	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.9	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.10	0	0.0012

t2(MVPA.tmat,MVPA.omat):L.MVPA.11	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.12	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.13	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.14	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.15	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.16	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.17	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.18	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.19	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.20	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.21	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.22	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.23	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.24	0	0.0013
t2(MVPA.tmat,MVPA.omat):L.MVPA.25	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.26	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.27	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.28	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.29	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.30	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.31	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.32	0	0.001

t2(MVPA.tmat,MVPA.omat):L.MVPA.33	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.34	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.35	1.0687	0.0317
t2(MVPA.tmat,MVPA.omat):L.MVPA.36	0.0002	0.1151
t2(MVPA.tmat,MVPA.omat):L.MVPA.37	-0.123	0.0037
t2(MVPA.tmat,MVPA.omat):L.MVPA.38	0.0028	0.115
t2(MVPA.tmat,MVPA.omat):L.MVPA.39	-1.3998	0.0415
t2(MVPA.tmat,MVPA.omat):L.MVPA.40	0.0332	0.1141
t2(MVPA.tmat,MVPA.omat):L.MVPA.41	-0.2206	0.0066
t2(MVPA.tmat,MVPA.omat):L.MVPA.42	-0.0057	0.1145
t2(MVPA.tmat,MVPA.omat):L.MVPA.43	10.0619	0.2981
t2(MVPA.tmat,MVPA.omat):L.MVPA.44	0.0442	0.1032
t2(MVPA.tmat,MVPA.omat):L.MVPA.45	0.2974	0.0781
t2(MVPA.tmat,MVPA.omat):L.MVPA.46	0.5677	0.2809
t2(MVPA.tmat,MVPA.omat):L.MVPA.47	-0.5547	0.0165
t2(MVPA.tmat,MVPA.omat):L.MVPA.48	0.6484	0.387
s(pfr_month_cos.tmat):L.pfr_month_cos.1	-0.0001	0.2867
s(pfr_month_cos.tmat):L.pfr_month_cos.2	-0.0001	0.2627
s(pfr_month_cos.tmat):L.pfr_month_cos.3	-0.0002	0.623
s(pfr_month_cos.tmat):L.pfr_month_cos.4	0.0003	0.7492
s(pfr_month_cos.tmat):L.pfr_month_cos.5	0.0002	0.5422
s(pfr_month_cos.tmat):L.pfr_month_cos.6	-1.6094	1.8354

s(pfr_month_cos.tmat):L.pfr_month_cos.7	-3.1231	5.9218
s(pfr_month_sin.tmat):L.pfr_month_sin.1	-8.7097	71.675
s(pfr_month_sin.tmat):L.pfr_month_sin.2	-1.0972	65.6637
s(pfr_month_sin.tmat):L.pfr_month_sin.3	0.0284	156.1398
s(pfr_month_sin.tmat):L.pfr_month_sin.4	12.0161	187.3235
s(pfr_month_sin.tmat):L.pfr_month_sin.5	7.3255	135.9212
s(pfr_month_sin.tmat):L.pfr_month_sin.6	19.7849	30.3586
s(pfr_month_sin.tmat):L.pfr_month_sin.7	6.1957	25.4692
s(pfr_participant).1	-0.8195	3.2219
s(pfr_participant).2	-3.3994	2.33
s(pfr_participant).3	-0.3429	3.0436
s(pfr_participant).4	-1.9507	1.8907
s(pfr_participant).5	-3.1004	1.8541
s(pfr_participant).6	2.7715	1.7634
s(pfr_participant).7	-4.7251	2.5942
s(pfr_participant).8	6.4256	2.302
s(pfr_participant).9	-2.2581	1.7001
s(pfr_participant).10	2.5425	2.4007
s(pfr_participant).11	-5.2992	2.2013
s(pfr_participant).12	7.0277	3.3273
s(pfr_participant).13	2.9095	2.0834
s(pfr_participant).14	1.1844	1.7011

s(pfr_participant).15	-0.7041	3.3855
s(pfr_participant).16	3.6399	1.6518
s(pfr_participant).17	1.327	3.2448
s(pfr_participant).18	0.2492	1.9396
s(pfr_participant).19	-0.6143	1.7548
s(pfr_participant).20	-3.9002	1.8232
s(pfr_participant).21	-3.2474	1.81
s(pfr_participant).22	3.3082	2.3462
s(pfr_participant).23	-1.9553	2.7352
s(pfr_participant).24	0.4892	3.3464
s(pfr_participant).25	-1.0614	2.0089
s(pfr_participant).26	7.3399	1.7229
s(pfr_participant).27	-2.2067	3.3497
s(pfr_participant).28	-2.5714	2.4798
s(pfr_participant).29	4.0968	2.4943
s(pfr_participant).30	3.2534	2.0713
s(pfr_participant).31	-1.0354	2.924
s(pfr_participant).32	1.6512	2.4759
s(pfr_participant).33	0.0849	1.7427
s(pfr_participant).34	0.9219	3.3273
s(pfr_participant).35	-1.5758	1.8535
s(pfr_participant).36	-1.1452	2.757

s(pfr_participant).37	7.3676	2.7764
s(pfr_participant).38	0.1432	3.0061
s(pfr_participant).39	-0.5169	2.8012
s(pfr_participant).40	-2.5837	3.4357
s(pfr_participant).41	-2.4264	1.8566
s(pfr_participant).42	7.4204	2.7515
s(pfr_participant).43	3.701	3.2246
s(pfr_participant).44	-2.3142	2.7271
s(pfr_participant).45	-1.4783	1.8362
s(pfr_participant).46	-0.8119	3.4236
s(pfr_participant).47	-2.91	2.2243
s(pfr_participant).48	-2.3047	2.7677
s(pfr_participant).49	-1.9364	2.7055
s(pfr_participant).50	-0.8793	3.229
s(pfr_participant).51	-1.9784	3.0708
s(pfr_participant).52	-8.8145	1.9939
s(pfr_participant).53	-0.1424	2.7878
s(pfr_participant).54	-4.7399	2.6715
s(pfr_participant).55	11.8348	1.8121
s(pfr_participant).56	-0.0268	3.1258
s(pfr_participant).57	-0.9704	1.8023
s(week).1	0	0.0008

635
636
637 **Table S3.** Linear predictors for the PFR model.
638

Predictor	Estimate	SE	T.value	P.value
(Intercept)	2.9429	0.0872	33.752	0
MPQ-VAS	-1.16	0.4964	-2.3368	0.0206
Physical Functioning	2.2409	0.598	3.7475	0.0002
Psychiatric Diagnosis	0.2181	0.8874	0.2458	0.8061
Employed	4.0117	1.0939	3.6674	0.0003
Employed - Other	6.0273	1.2929	4.6617	0
Divorced	0.3939	1.8963	0.2077	0.8357
Married	3.5996	0.8582	4.1946	0
Age	-1.1946	0.4629	-2.5804	0.0107